This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.
compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a fast-track review by the US FDA. ... AZ and Lilly are already carrying out one phase II/III placebo-controlled trial of AZD3293
others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.
Lilly's neuroscience R&D portfolio is headed by its Alzheimer's disease (AD) programmes, which include seven candidates headed by AstraZeneca-partnered BACE inhibitor AZD3293, and has recently started phase
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...